CN112574952A - 一种工程化人体免疫细胞、其制备方法及应用 - Google Patents
一种工程化人体免疫细胞、其制备方法及应用 Download PDFInfo
- Publication number
- CN112574952A CN112574952A CN201910945529.3A CN201910945529A CN112574952A CN 112574952 A CN112574952 A CN 112574952A CN 201910945529 A CN201910945529 A CN 201910945529A CN 112574952 A CN112574952 A CN 112574952A
- Authority
- CN
- China
- Prior art keywords
- cells
- cell
- human
- itnk
- mature
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000002865 immune cell Anatomy 0.000 title abstract description 24
- 238000002360 preparation method Methods 0.000 title abstract description 9
- 210000001744 T-lymphocyte Anatomy 0.000 claims abstract description 207
- 210000000822 natural killer cell Anatomy 0.000 claims abstract description 82
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 31
- 230000008672 reprogramming Effects 0.000 claims abstract description 23
- 210000004698 lymphocyte Anatomy 0.000 claims abstract description 22
- 101100493743 Homo sapiens BCL11B gene Proteins 0.000 claims abstract description 18
- 230000006870 function Effects 0.000 claims abstract description 15
- 230000002147 killing effect Effects 0.000 claims abstract description 10
- 238000012217 deletion Methods 0.000 claims abstract description 9
- 230000037430 deletion Effects 0.000 claims abstract description 9
- 210000004027 cell Anatomy 0.000 claims description 238
- 230000014509 gene expression Effects 0.000 claims description 50
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 claims description 33
- 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 claims description 33
- 210000004700 fetal blood Anatomy 0.000 claims description 27
- 102100032870 Natural cytotoxicity triggering receptor 1 Human genes 0.000 claims description 26
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 claims description 25
- 210000005259 peripheral blood Anatomy 0.000 claims description 25
- 239000011886 peripheral blood Substances 0.000 claims description 25
- 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 claims description 24
- 108010004217 Natural Cytotoxicity Triggering Receptor 1 Proteins 0.000 claims description 22
- 238000003209 gene knockout Methods 0.000 claims description 18
- 238000000034 method Methods 0.000 claims description 18
- 108010004222 Natural Cytotoxicity Triggering Receptor 3 Proteins 0.000 claims description 16
- 102100032852 Natural cytotoxicity triggering receptor 3 Human genes 0.000 claims description 16
- 230000001105 regulatory effect Effects 0.000 claims description 16
- 101000589305 Homo sapiens Natural cytotoxicity triggering receptor 2 Proteins 0.000 claims description 12
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims description 12
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims description 12
- 230000004913 activation Effects 0.000 claims description 12
- 102100032851 Natural cytotoxicity triggering receptor 2 Human genes 0.000 claims description 11
- 108091033409 CRISPR Proteins 0.000 claims description 10
- 102100025237 T-cell surface antigen CD2 Human genes 0.000 claims description 9
- 101001081582 Homo sapiens DNA-binding protein inhibitor ID-2 Proteins 0.000 claims description 8
- 239000006143 cell culture medium Substances 0.000 claims description 8
- 239000003550 marker Substances 0.000 claims description 8
- 239000000203 mixture Substances 0.000 claims description 8
- 208000035473 Communicable disease Diseases 0.000 claims description 7
- 102100027642 DNA-binding protein inhibitor ID-2 Human genes 0.000 claims description 7
- 108010070047 Notch Receptors Proteins 0.000 claims description 7
- 102000005650 Notch Receptors Human genes 0.000 claims description 7
- 230000001506 immunosuppresive effect Effects 0.000 claims description 7
- 230000011664 signaling Effects 0.000 claims description 7
- 101000713602 Homo sapiens T-box transcription factor TBX21 Proteins 0.000 claims description 6
- 102100036840 T-box transcription factor TBX21 Human genes 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 6
- 230000019491 signal transduction Effects 0.000 claims description 6
- 238000011282 treatment Methods 0.000 claims description 6
- 102100027581 Forkhead box protein P3 Human genes 0.000 claims description 5
- 101000861452 Homo sapiens Forkhead box protein P3 Proteins 0.000 claims description 5
- 101000746373 Homo sapiens Granulocyte-macrophage colony-stimulating factor Proteins 0.000 claims description 5
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 claims description 5
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 claims description 5
- 108010002350 Interleukin-2 Proteins 0.000 claims description 5
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 claims description 5
- 239000011324 bead Substances 0.000 claims description 5
- 210000001671 embryonic stem cell Anatomy 0.000 claims description 5
- 208000015181 infectious disease Diseases 0.000 claims description 5
- 210000001778 pluripotent stem cell Anatomy 0.000 claims description 5
- 238000010354 CRISPR gene editing Methods 0.000 claims description 4
- 108010021064 CTLA-4 Antigen Proteins 0.000 claims description 4
- 229940045513 CTLA4 antagonist Drugs 0.000 claims description 4
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 claims description 4
- 101001043809 Homo sapiens Interleukin-7 receptor subunit alpha Proteins 0.000 claims description 4
- 101000589301 Homo sapiens Natural cytotoxicity triggering receptor 1 Proteins 0.000 claims description 4
- 101000973177 Homo sapiens Nuclear factor interleukin-3-regulated protein Proteins 0.000 claims description 4
- 102100022297 Integrin alpha-X Human genes 0.000 claims description 4
- 102100021593 Interleukin-7 receptor subunit alpha Human genes 0.000 claims description 4
- 102100022163 Nuclear factor interleukin-3-regulated protein Human genes 0.000 claims description 4
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims description 4
- 102100040678 Programmed cell death protein 1 Human genes 0.000 claims description 4
- 230000003213 activating effect Effects 0.000 claims description 4
- 238000012258 culturing Methods 0.000 claims description 4
- 230000004069 differentiation Effects 0.000 claims description 4
- 201000010099 disease Diseases 0.000 claims description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 4
- 238000005516 engineering process Methods 0.000 claims description 4
- 230000001404 mediated effect Effects 0.000 claims description 4
- 210000000130 stem cell Anatomy 0.000 claims description 4
- 230000001988 toxicity Effects 0.000 claims description 4
- 231100000419 toxicity Toxicity 0.000 claims description 4
- 102100026210 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-2 Human genes 0.000 claims description 3
- 102100032937 CD40 ligand Human genes 0.000 claims description 3
- 102100030385 Granzyme B Human genes 0.000 claims description 3
- 101000691589 Homo sapiens 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-2 Proteins 0.000 claims description 3
- 101000868215 Homo sapiens CD40 ligand Proteins 0.000 claims description 3
- 101001009603 Homo sapiens Granzyme B Proteins 0.000 claims description 3
- 101000599940 Homo sapiens Interferon gamma Proteins 0.000 claims description 3
- 101000972291 Homo sapiens Lymphoid enhancer-binding factor 1 Proteins 0.000 claims description 3
- 101001109501 Homo sapiens NKG2-D type II integral membrane protein Proteins 0.000 claims description 3
- 101000987581 Homo sapiens Perforin-1 Proteins 0.000 claims description 3
- 101000861454 Homo sapiens Protein c-Fos Proteins 0.000 claims description 3
- 102100037850 Interferon gamma Human genes 0.000 claims description 3
- 102000003814 Interleukin-10 Human genes 0.000 claims description 3
- 108090000174 Interleukin-10 Proteins 0.000 claims description 3
- 102100022699 Lymphoid enhancer-binding factor 1 Human genes 0.000 claims description 3
- 102100022680 NKG2-D type II integral membrane protein Human genes 0.000 claims description 3
- 102100027584 Protein c-Fos Human genes 0.000 claims description 3
- 230000005859 cell recognition Effects 0.000 claims description 3
- 230000003247 decreasing effect Effects 0.000 claims description 3
- FOCAHLGSDWHSAH-UHFFFAOYSA-N difluoromethanethione Chemical compound FC(F)=S FOCAHLGSDWHSAH-UHFFFAOYSA-N 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 102100022132 High affinity immunoglobulin epsilon receptor subunit gamma Human genes 0.000 claims description 2
- 101000824104 Homo sapiens High affinity immunoglobulin epsilon receptor subunit gamma Proteins 0.000 claims description 2
- 101000599852 Homo sapiens Intercellular adhesion molecule 1 Proteins 0.000 claims description 2
- 101000945331 Homo sapiens Killer cell immunoglobulin-like receptor 2DL4 Proteins 0.000 claims description 2
- 101000628967 Homo sapiens Mitogen-activated protein kinase 11 Proteins 0.000 claims description 2
- 101000628954 Homo sapiens Mitogen-activated protein kinase 12 Proteins 0.000 claims description 2
- 101001055091 Homo sapiens Mitogen-activated protein kinase kinase kinase 8 Proteins 0.000 claims description 2
- 101000961071 Homo sapiens NF-kappa-B inhibitor alpha Proteins 0.000 claims description 2
- 101000884270 Homo sapiens Natural killer cell receptor 2B4 Proteins 0.000 claims description 2
- 101000653540 Homo sapiens Transcription factor 7 Proteins 0.000 claims description 2
- 101000604583 Homo sapiens Tyrosine-protein kinase SYK Proteins 0.000 claims description 2
- 101000889732 Homo sapiens Tyrosine-protein kinase Tec Proteins 0.000 claims description 2
- 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 claims description 2
- 102100033633 Killer cell immunoglobulin-like receptor 2DL4 Human genes 0.000 claims description 2
- 102100026929 Mitogen-activated protein kinase 11 Human genes 0.000 claims description 2
- 102100026932 Mitogen-activated protein kinase 12 Human genes 0.000 claims description 2
- 102100026907 Mitogen-activated protein kinase kinase kinase 8 Human genes 0.000 claims description 2
- 102100039337 NF-kappa-B inhibitor alpha Human genes 0.000 claims description 2
- 102100038082 Natural killer cell receptor 2B4 Human genes 0.000 claims description 2
- 102100022673 Nuclear receptor subfamily 4 group A member 3 Human genes 0.000 claims description 2
- 210000000662 T-lymphocyte subset Anatomy 0.000 claims description 2
- 102100038183 Tyrosine-protein kinase SYK Human genes 0.000 claims description 2
- 230000003612 virological effect Effects 0.000 claims description 2
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 claims 1
- 101000959820 Homo sapiens Interferon alpha-1/13 Proteins 0.000 claims 1
- 102100040019 Interferon alpha-1/13 Human genes 0.000 claims 1
- 230000000984 immunochemical effect Effects 0.000 claims 1
- 239000000427 antigen Substances 0.000 abstract description 8
- 102000036639 antigens Human genes 0.000 abstract description 8
- 108091007433 antigens Proteins 0.000 abstract description 8
- 238000001228 spectrum Methods 0.000 abstract description 4
- 230000003321 amplification Effects 0.000 abstract description 3
- 238000000338 in vitro Methods 0.000 abstract description 3
- 238000003199 nucleic acid amplification method Methods 0.000 abstract description 3
- 241000894006 Bacteria Species 0.000 abstract description 2
- 241000700605 Viruses Species 0.000 abstract description 2
- 244000005700 microbiome Species 0.000 abstract description 2
- 108020004414 DNA Proteins 0.000 description 51
- 108091008874 T cell receptors Proteins 0.000 description 28
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 28
- 108090000623 proteins and genes Proteins 0.000 description 27
- 102100022983 B-cell lymphoma/leukemia 11B Human genes 0.000 description 23
- 101000903697 Homo sapiens B-cell lymphoma/leukemia 11B Proteins 0.000 description 23
- 230000002441 reversible effect Effects 0.000 description 18
- 238000004458 analytical method Methods 0.000 description 17
- 241000699670 Mus sp. Species 0.000 description 13
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 description 11
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 description 11
- 238000012163 sequencing technique Methods 0.000 description 11
- 239000013598 vector Substances 0.000 description 11
- 238000000684 flow cytometry Methods 0.000 description 9
- 238000001727 in vivo Methods 0.000 description 9
- 210000004475 gamma-delta t lymphocyte Anatomy 0.000 description 8
- 230000000638 stimulation Effects 0.000 description 8
- 108010050904 Interferons Proteins 0.000 description 7
- 102000014150 Interferons Human genes 0.000 description 7
- 238000003559 RNA-seq method Methods 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 229940079322 interferon Drugs 0.000 description 7
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 7
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 6
- 102000027581 NK cell receptors Human genes 0.000 description 6
- 108091008877 NK cell receptors Proteins 0.000 description 6
- 201000011510 cancer Diseases 0.000 description 6
- 102000005962 receptors Human genes 0.000 description 6
- 108020003175 receptors Proteins 0.000 description 6
- 230000007704 transition Effects 0.000 description 6
- 210000004881 tumor cell Anatomy 0.000 description 6
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 5
- 108020005004 Guide RNA Proteins 0.000 description 5
- 108091023040 Transcription factor Proteins 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 239000002771 cell marker Substances 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 238000009169 immunotherapy Methods 0.000 description 5
- 230000028327 secretion Effects 0.000 description 5
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- 102000004127 Cytokines Human genes 0.000 description 4
- 108090000695 Cytokines Proteins 0.000 description 4
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 4
- 102000040945 Transcription factor Human genes 0.000 description 4
- 210000001185 bone marrow Anatomy 0.000 description 4
- 238000009826 distribution Methods 0.000 description 4
- 239000012091 fetal bovine serum Substances 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 238000001262 western blot Methods 0.000 description 4
- 208000023275 Autoimmune disease Diseases 0.000 description 3
- 102000008203 CTLA-4 Antigen Human genes 0.000 description 3
- 101001027081 Homo sapiens Killer cell immunoglobulin-like receptor 2DL1 Proteins 0.000 description 3
- 101000945333 Homo sapiens Killer cell immunoglobulin-like receptor 2DL3 Proteins 0.000 description 3
- 101000945351 Homo sapiens Killer cell immunoglobulin-like receptor 3DL1 Proteins 0.000 description 3
- 101000945490 Homo sapiens Killer cell immunoglobulin-like receptor 3DL2 Proteins 0.000 description 3
- 102000000588 Interleukin-2 Human genes 0.000 description 3
- 108010043610 KIR Receptors Proteins 0.000 description 3
- 102100037363 Killer cell immunoglobulin-like receptor 2DL1 Human genes 0.000 description 3
- 102100033634 Killer cell immunoglobulin-like receptor 2DL3 Human genes 0.000 description 3
- 102100033627 Killer cell immunoglobulin-like receptor 3DL1 Human genes 0.000 description 3
- 102100034840 Killer cell immunoglobulin-like receptor 3DL2 Human genes 0.000 description 3
- 102100030627 Transcription factor 7 Human genes 0.000 description 3
- 102100023118 Transcription factor JunD Human genes 0.000 description 3
- 102000006707 alpha-beta T-Cell Antigen Receptors Human genes 0.000 description 3
- 108010087408 alpha-beta T-Cell Antigen Receptors Proteins 0.000 description 3
- 230000003915 cell function Effects 0.000 description 3
- 238000002659 cell therapy Methods 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 239000012636 effector Substances 0.000 description 3
- 102000011778 gamma-delta T-Cell Antigen Receptors Human genes 0.000 description 3
- 108010062214 gamma-delta T-Cell Antigen Receptors Proteins 0.000 description 3
- 238000003119 immunoblot Methods 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 238000000513 principal component analysis Methods 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 238000004454 trace mineral analysis Methods 0.000 description 3
- 238000002054 transplantation Methods 0.000 description 3
- 238000011870 unpaired t-test Methods 0.000 description 3
- 230000003827 upregulation Effects 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- RDEIXVOBVLKYNT-VQBXQJRRSA-N (2r,3r,4r,5r)-2-[(1s,2s,3r,4s,6r)-4,6-diamino-3-[(2r,3r,6s)-3-amino-6-(1-aminoethyl)oxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol;(2r,3r,4r,5r)-2-[(1s,2s,3r,4s,6r)-4,6-diamino-3-[(2r,3r,6s)-3-amino-6-(aminomethyl)oxan-2-yl]o Chemical compound OS(O)(=O)=O.O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H](CC[C@@H](CN)O2)N)[C@@H](N)C[C@H]1N.O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H](CC[C@H](O2)C(C)N)N)[C@@H](N)C[C@H]1N.O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N RDEIXVOBVLKYNT-VQBXQJRRSA-N 0.000 description 2
- -1 CCL4 Proteins 0.000 description 2
- 101100506090 Caenorhabditis elegans hil-2 gene Proteins 0.000 description 2
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 description 2
- 238000001712 DNA sequencing Methods 0.000 description 2
- 101001055145 Homo sapiens Interleukin-2 receptor subunit beta Proteins 0.000 description 2
- 101000584743 Homo sapiens Recombining binding protein suppressor of hairless Proteins 0.000 description 2
- 101000595467 Homo sapiens T-complex protein 1 subunit gamma Proteins 0.000 description 2
- 101001028730 Homo sapiens Transcription factor JunB Proteins 0.000 description 2
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 description 2
- 101000915477 Homo sapiens Zinc finger MIZ domain-containing protein 1 Proteins 0.000 description 2
- 101150069255 KLRC1 gene Proteins 0.000 description 2
- 108060001084 Luciferase Proteins 0.000 description 2
- 239000005089 Luciferase Substances 0.000 description 2
- 101100404845 Macaca mulatta NKG2A gene Proteins 0.000 description 2
- 102100022682 NKG2-A/NKG2-B type II integral membrane protein Human genes 0.000 description 2
- 102100030000 Recombining binding protein suppressor of hairless Human genes 0.000 description 2
- 102100036049 T-complex protein 1 subunit gamma Human genes 0.000 description 2
- 238000003917 TEM image Methods 0.000 description 2
- 102000013530 TOR Serine-Threonine Kinases Human genes 0.000 description 2
- 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 description 2
- 102100037168 Transcription factor JunB Human genes 0.000 description 2
- 102100040247 Tumor necrosis factor Human genes 0.000 description 2
- 102100028535 Zinc finger MIZ domain-containing protein 1 Human genes 0.000 description 2
- 210000002203 alpha-beta t lymphocyte Anatomy 0.000 description 2
- 210000003855 cell nucleus Anatomy 0.000 description 2
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 210000004443 dendritic cell Anatomy 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 210000003162 effector t lymphocyte Anatomy 0.000 description 2
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 2
- 230000017188 evasion or tolerance of host immune response Effects 0.000 description 2
- 238000005206 flow analysis Methods 0.000 description 2
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 238000003018 immunoassay Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 238000002826 magnetic-activated cell sorting Methods 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 239000013600 plasmid vector Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 210000003289 regulatory T cell Anatomy 0.000 description 2
- 230000000284 resting effect Effects 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- 102000015936 AP-1 transcription factor Human genes 0.000 description 1
- 108050004195 AP-1 transcription factor Proteins 0.000 description 1
- 108010074708 B7-H1 Antigen Proteins 0.000 description 1
- 102100036848 C-C motif chemokine 20 Human genes 0.000 description 1
- 102100025279 C-X-C motif chemokine 11 Human genes 0.000 description 1
- 101100380241 Caenorhabditis elegans arx-2 gene Proteins 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 239000012625 DNA intercalator Substances 0.000 description 1
- 108010087819 Fc receptors Proteins 0.000 description 1
- 102000009109 Fc receptors Human genes 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- 102100020997 Fractalkine Human genes 0.000 description 1
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 description 1
- 101710083479 Hepatitis A virus cellular receptor 2 homolog Proteins 0.000 description 1
- 108010020382 Hepatocyte Nuclear Factor 1-alpha Proteins 0.000 description 1
- 102000008949 Histocompatibility Antigens Class I Human genes 0.000 description 1
- 108010088652 Histocompatibility Antigens Class I Proteins 0.000 description 1
- 102100027368 Histone H1.3 Human genes 0.000 description 1
- 102100039265 Histone H2A type 1-C Human genes 0.000 description 1
- 108010033040 Histones Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000713099 Homo sapiens C-C motif chemokine 20 Proteins 0.000 description 1
- 101000858060 Homo sapiens C-X-C motif chemokine 11 Proteins 0.000 description 1
- 101000854520 Homo sapiens Fractalkine Proteins 0.000 description 1
- 101001045751 Homo sapiens Hepatocyte nuclear factor 1-alpha Proteins 0.000 description 1
- 101001009450 Homo sapiens Histone H1.3 Proteins 0.000 description 1
- 101001036109 Homo sapiens Histone H2A type 1-C Proteins 0.000 description 1
- 101100341519 Homo sapiens ITGAX gene Proteins 0.000 description 1
- 101001032345 Homo sapiens Interferon regulatory factor 8 Proteins 0.000 description 1
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 1
- 101001002634 Homo sapiens Interleukin-1 alpha Proteins 0.000 description 1
- 101000998146 Homo sapiens Interleukin-17A Proteins 0.000 description 1
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 1
- 101000945371 Homo sapiens Killer cell immunoglobulin-like receptor 2DL2 Proteins 0.000 description 1
- 101001000302 Homo sapiens Max-interacting protein 1 Proteins 0.000 description 1
- 101001030211 Homo sapiens Myc proto-oncogene protein Proteins 0.000 description 1
- 101001050297 Homo sapiens Transcription factor JunD Proteins 0.000 description 1
- 101000679851 Homo sapiens Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 description 1
- 108091058560 IL8 Proteins 0.000 description 1
- 102000037982 Immune checkpoint proteins Human genes 0.000 description 1
- 108091008036 Immune checkpoint proteins Proteins 0.000 description 1
- 102100038069 Interferon regulatory factor 8 Human genes 0.000 description 1
- 102100027268 Interferon-stimulated gene 20 kDa protein Human genes 0.000 description 1
- 102100020881 Interleukin-1 alpha Human genes 0.000 description 1
- 108010065805 Interleukin-12 Proteins 0.000 description 1
- 102000013462 Interleukin-12 Human genes 0.000 description 1
- 108090000176 Interleukin-13 Proteins 0.000 description 1
- 102000003816 Interleukin-13 Human genes 0.000 description 1
- 102100033461 Interleukin-17A Human genes 0.000 description 1
- 102100026879 Interleukin-2 receptor subunit beta Human genes 0.000 description 1
- 102100030704 Interleukin-21 Human genes 0.000 description 1
- 108010065637 Interleukin-23 Proteins 0.000 description 1
- 102000013264 Interleukin-23 Human genes 0.000 description 1
- 102000004388 Interleukin-4 Human genes 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 102000000743 Interleukin-5 Human genes 0.000 description 1
- 108010002616 Interleukin-5 Proteins 0.000 description 1
- 102000004889 Interleukin-6 Human genes 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 102000000704 Interleukin-7 Human genes 0.000 description 1
- 108010002586 Interleukin-7 Proteins 0.000 description 1
- 102000004890 Interleukin-8 Human genes 0.000 description 1
- 108090001007 Interleukin-8 Proteins 0.000 description 1
- 102000002698 KIR Receptors Human genes 0.000 description 1
- 102100033599 Killer cell immunoglobulin-like receptor 2DL2 Human genes 0.000 description 1
- 108090001093 Lymphoid enhancer-binding factor 1 Proteins 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 101150018665 MAPK3 gene Proteins 0.000 description 1
- 102100035880 Max-interacting protein 1 Human genes 0.000 description 1
- 102100038895 Myc proto-oncogene protein Human genes 0.000 description 1
- 108091008043 NK cell inhibitory receptors Proteins 0.000 description 1
- 206010061309 Neoplasm progression Diseases 0.000 description 1
- 230000005913 Notch signaling pathway Effects 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 102100028467 Perforin-1 Human genes 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 description 1
- 206010037211 Psychomotor hyperactivity Diseases 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 108091081021 Sense strand Proteins 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 230000006044 T cell activation Effects 0.000 description 1
- 108010029625 T-Box Domain Protein 2 Proteins 0.000 description 1
- 102100038721 T-box transcription factor TBX2 Human genes 0.000 description 1
- 229940126547 T-cell immunoglobulin mucin-3 Drugs 0.000 description 1
- 108050005484 Transcription factor 7 Proteins 0.000 description 1
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 101150092805 actc1 gene Proteins 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 230000004721 adaptive immunity Effects 0.000 description 1
- 230000001745 anti-biotin effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000029918 bioluminescence Effects 0.000 description 1
- 238000005415 bioluminescence Methods 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000011712 cell development Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000007910 cell fusion Effects 0.000 description 1
- 230000022534 cell killing Effects 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 230000009028 cell transition Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 238000011281 clinical therapy Methods 0.000 description 1
- 238000003340 combinatorial analysis Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000000432 density-gradient centrifugation Methods 0.000 description 1
- 238000009795 derivation Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000012154 double-distilled water Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 238000010201 enrichment analysis Methods 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 238000010362 genome editing Methods 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000005934 immune activation Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000008629 immune suppression Effects 0.000 description 1
- 238000013394 immunophenotyping Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 239000000138 intercalating agent Substances 0.000 description 1
- 108010074108 interleukin-21 Proteins 0.000 description 1
- 108040006861 interleukin-7 receptor activity proteins Proteins 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000010859 live-cell imaging Methods 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 238000012083 mass cytometry Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 1
- 230000004719 natural immunity Effects 0.000 description 1
- 210000000581 natural killer T-cell Anatomy 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 238000007427 paired t-test Methods 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 238000003068 pathway analysis Methods 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000012174 single-cell RNA sequencing Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000001360 synchronised effect Effects 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 238000012085 transcriptional profiling Methods 0.000 description 1
- 238000011222 transcriptome analysis Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 230000005909 tumor killing Effects 0.000 description 1
- 230000005751 tumor progression Effects 0.000 description 1
- 229910021642 ultra pure water Inorganic materials 0.000 description 1
- 239000012498 ultrapure water Substances 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 238000012070 whole genome sequencing analysis Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0646—Natural killers cells [NK], NKT cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4613—Natural-killer cells [NK or NK-T]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
- C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases RNAses, DNAses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPRs]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/32—Amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2302—Interleukin-2 (IL-2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/51—B7 molecules, e.g. CD80, CD86, CD28 (ligand), CD152 (ligand)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/515—CD3, T-cell receptor complex
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/53—CD2
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/998—Proteins not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/11—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from blood or immune system cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/80—Vectors containing sites for inducing double-stranded breaks, e.g. meganuclease restriction sites
Abstract
本发明公开了一种工程化人体免疫细胞、其制备方法及应用。本发明所述工程化人体免疫细胞是通过重编程人T细胞诱导而成的免疫杀伤淋巴细胞,其保留衍生其的人T细胞的标志物和功能并具有NK细胞的标志物和功能,其中,所述人T细胞的重编程涉及BCL11B基因的缺失。与T细胞和NK细胞相比,所述工程化人体免疫细胞不仅具有更广谱的肿瘤抗原识别杀伤功能,而且还具有更广谱的病毒、细菌等微生物识别清除功能,并具有高效的体外扩增能力。
Description
技术领域
本发明涉及生物医药技术领域,具体涉及一种工程化人体免疫细胞、其制备方法及应用。
背景技术
目前,免疫疗法已成为癌症治疗领域中最受关注和最有希望的“新”想法。2013年《科学》杂志评出的年度十大科学突破排行榜中,肿瘤免疫治疗高居榜首。诺华和凯特公司的嵌合抗原受体(CAR,Chimeric Antigen Receptor)T细胞被美国FDA批准上市,肿瘤免疫细胞治疗在血液恶性癌症治疗领域取得了里程碑式进展。然而,肿瘤免疫细胞治疗仍然存在临床治疗的技术瓶颈,如基因修饰免疫细胞的靶点单一等原因导致肿瘤免疫逃逸,肿瘤复发;如实体肿瘤缺乏高效、低副作用的特异性标志物,目前的基因修饰免疫细胞治疗对实体肿瘤均未见高效、安全的临床疗效。
T细胞根据其表面标志和功能的差异,可分为不同的亚群;如根据TCR类型差异可分为γδT细胞和αβT细胞。αβT细胞占T细胞95%以上,是体内具有T细胞分化标记、执行T细胞功能主要的细胞群,代表了T细胞的多样性。而γδT细胞是一群高度异质性细胞,其表面T细胞受体由γ链和δ链组成,其亚类种类多、表型多变、功能丰富,γδT细胞各亚类间生物学特性各异,在机体肿瘤、感染及自身免疫性疾病等的发生、发展中均有重要作用,被认为是机体连接天然免疫与适应性免疫功能的桥梁。
像T细胞一样,自然杀伤(NK)细胞是人体免疫系统中不可或缺的一部分。NK细胞被认为是占外周血淋巴细胞约10-15%且在天然免疫响应中起关键作用的淋巴样细胞。与T细胞不同的是,NK细胞以MHC非限制性方式识别其靶标。NK细胞可呈现抗病毒作用、抗GvH作用和抗癌作用,具体地,NK细胞直接杀伤恶性肿瘤,包括肉瘤、骨髓瘤、癌、淋巴瘤和白血病,或有助于通过诱导树突状细胞(DC)活性或肿瘤特异性细胞毒性T淋巴细胞(CTL)的适应性免疫活化,由此消除异常细胞,所述异常细胞为肿瘤细胞或正发展成为肿瘤细胞的细胞。尽管NK细胞具有作为对抗癌症或感染性疾病的治疗剂的潜力,但是正常人体内大多的NK细胞以休眠状态存在,且癌症患者内的NK细胞由于癌细胞的免疫逃逸机制缺少其功能。为将自然杀伤细胞实际应用为治疗剂,需要能够识别并破坏肿瘤细胞的活化的自然杀伤细胞,且由于体内的自然杀伤细胞数目有限,因此,获得足够数量的活化的自然杀伤细胞是非常重要的。
细胞重编程(cell reprogramming)指的是分化的细胞在特定的条件下被逆转后恢复到全能性状态,或者形成胚胎干细胞系,或者进一步发育成一个新的个体的过程。在疾病的免疫治疗领域,已有通过细胞重编程来实现免疫细胞的类型转化的相关报道。例如,美国格拉斯通研究所(Gladstone Institutes)的丁胜博士曾报道,通过特定的重编程方法,将促炎的效应T细胞重编程为抗炎的调节性T细胞;这种重编程对于自身免疫性疾病的治疗意义重大,具体地,在自身免疫性疾病中,被过度激发的效应T细胞会对机体造成损害,将这些细胞转化为调节性T细胞有助于减少免疫系统的过度活跃,使其恢复平衡,从而根本上治疗疾病。
目前,尚未见细胞重编程技术在人类肿瘤免疫治疗中的应用。
发明内容
针对现有技术的不足及实际的需求,本发明提供了一种通过重编程工程化的人体免疫细胞、其制备方法及应用。本发明的工程化人体免疫细胞兼具T细胞和NK细胞的部分标志物和功能,同时表达NK细胞和T细胞的抗原识别杀伤受体,因而,比NK细胞和T细胞本身具有更广谱的肿瘤抗原识别杀伤功能;同时,相较于衍生其的人成熟T细胞,本发明的工程化人体免疫细胞扩增能力增强,抗肿瘤效果更好。
在第一方面,本发明提过了通过重编程人T细胞诱导而成的免疫杀伤淋巴细胞(ITNK),其保留衍生其的T细胞的标志物和功能并具有NK细胞的标志物和功能,其中,所述人T细胞的重编程涉及BCL11B基因的缺失。
优选地,所述人T细胞为成熟的人T细胞或含有成熟人T细胞的细胞群;进一步优选地,所述成熟人T细胞或含有成熟人T细胞的细胞群来源于人体脐带血或外周血;进一步优选地,所述成熟人T细胞或含有成熟人T细胞的细胞群来源于多能干细胞、胚胎干细胞或脐带血干细胞分化获得的成熟T细胞或细胞群。
优选地,所述重编程的免疫杀伤淋巴细胞表达功能性的TCR、CD3和NKp30。
优选地,所述重编程的免疫杀伤淋巴细胞表达选自以下的NK细胞的标志物:CD11c、NKG2D和CD161。
优选地,所述重编程的免疫杀伤淋巴细胞低表达或不表达PD-1、CTLA-4或FOXP3免疫抑制检查点。
优选地,所述重编程的免疫杀伤淋巴细胞低表达或不表达NK相关标志物:CD127、CD16、KIRDL2、KIRDL3、NKG2A。
优选地,相较于衍生其的T细胞,所述重编程的免疫杀伤淋巴细胞的NOTCH表达上调。
优选地,相较于衍生其的T细胞,所述重编程的免疫杀伤淋巴细胞中,LEF1和TCF7转录因子表达下降,NOTCH、AP1、mTOR、ID2、TBX21和NFIL3表达上升。
优选地,所述重编程的免疫杀伤淋巴细胞的TCR介导的信号转导增强;
优选地,相较于衍生其的T细胞,所述重编程的免疫杀伤淋巴细胞的与TCR介导的信号转导相关的基因CSF2、FOS、MAPK12、MAP3K8、IFNγ、NFKBIA、MAPK11、IL-10和TEC的表达上调。
优选地,相对于NK细胞,所述重编程的免疫杀伤淋巴细胞的T细胞识别和TCR信号转导增强,优选地,CD3、CD4、CD8、CD40LG的表达上调。
优选地,相较于衍生其的T细胞,所述重编程的免疫杀伤淋巴细胞的NK杀伤毒性相关信号转导增强;
优选地,相较于衍生其的T细胞,所述重编程的免疫杀伤淋巴细胞的与NK杀伤毒性相关信号转导相关的基因PRF1、CSF2、ICAM1、CD244、PLCG2、IFNG、FCER1G、GZMB、NCR2、NCR1、KIR2DL4和SYK的表达上调。
在一个优选的具体实施方案中,所述重编程的免疫杀伤淋巴细胞包括CD8+NKp46hiNKp44+NKp30+、CD4+NKp30+和γδTCR+NKp46hiNKp44+NKp30+T细胞亚群。
在一个优选的具体实施方案中,所述人T细胞为成熟人T细胞,并且重编程所述人成熟T细胞包括:
1)激活成熟人T细胞;
2)对步骤1)所得激活的成熟人T细胞实施BCL11B基因敲除;
3)将步骤2)所得细胞用T细胞培养基进行培养。
其中,步骤1)中,使用抗人CD3抗体、抗人CD28抗体和抗人CD2抗体进行激活;
优选地,使用抗人CD3抗体、抗人CD28抗体和抗人CD2抗体的磁珠与人成熟T细胞以1:2混合孵育激活T细胞。
其中,步骤2)中,使用CRISPR/CAS9技术进行BCL11B基因敲除;
优选地,所述基因敲除的靶点在BCL11B基因的第二外显子和/或第三外显子处。
其中,步骤3)中,所述T细胞培养基包含IL-2;优选地,不与OP9-DL1进行共培养。
第二方面,本发明提供了一种制备上述第一方面所述的细胞的方法,其包括:
1’)激活人T细胞;
2’)对步骤1’)所得激活的人T细胞实施BCL11B基因敲除;
3’)将步骤2’)所得细胞用T细胞培养基进行培养。
上述方法中,优选地,所述人T细胞为成熟人T细胞或含有成熟人T细胞的细胞群;进一步优选地,所述成熟人T细胞或含有成熟人T细胞的细胞群来源于人体脐带血或外周血;进一步优选地,所述成熟人T细胞或含有成熟人T细胞的细胞群来源于多能干细胞、胚胎干细胞或脐带血干细胞分化获得的成熟T细胞或细胞群。
上述方法中,优选地,步骤1’)中,使用抗人CD3抗体、抗人CD28抗体和抗人CD2抗体进行激活;在一个优选的具体实施方案中,使用抗人CD3抗体、抗人CD28抗体和抗人CD2抗体的磁珠与人成熟T细胞以1:2混合孵育激活T细胞。
优选地,步骤2’)中,使用CRISPR/CAS9技术进行BCL11B基因敲除;进一步优选地,在BCL11B基因的第二外显子和/或第三外显子处进行基因敲除。
优选地,步骤3’)中,所述T细胞培养基包含IL-2;优选地,不与OP9-DL1进行共培养。
第三方面,本发明还提供了如上述第一方面所述的细胞在制备治疗选自以下的疾病的药物中的用途:肿瘤、艾滋病和感染性疾病;优选地,所述感染性疾病为病毒感染性疾病。
优选地,所述药物还包含药学上可接受的赋形剂。
本申请首次实现了将人T细胞重编程为免疫杀伤淋巴细胞,重编程后的细胞同时表达NK细胞和T细胞的抗原识别杀伤受体,特别是功能性TCR,同时具备T细胞和NK细胞功能;由于其同时表达NK细胞和T细胞的抗原识别杀伤受体,所以可识别这些受体敏感的抗原,相对于T细胞和NK细胞,不仅具有更广谱的肿瘤抗原识别杀伤功能,而且还具有更广谱的病毒、细菌等微生物识别清除功能。
此外,本申请的重编程后的细胞具有高效的体外扩增能力。在过继细胞转移(ACT)治疗中,T细胞和NK细胞都被用于治疗癌症。本申请的重编程后的细胞兼具T细胞和NK细胞的功能,相较于NK细胞应用于过继性免疫治疗(ACT)时的可用性和扩增能力限制,使用者可从患者的外周血中获得大量的T细胞来产生本申请的重编程的免疫杀伤淋巴细胞,并在2~3周内,即可从实体瘤患者约100×106个外周血单核细胞中制备获取200-1248×106个重编程的免疫杀伤淋巴细胞,达到患者回输细胞的需求量。
附图说明
图1是本发明实施例1中所构建的PX458-gBCL11B载体的示意图。
图2是基因测序检测并验证转导了PX458-gBCL11B的T细胞的BCL11B外显子是否被敲除的图示,对照组为转导了PX458空载体(Mock)的T细胞。
图3是Western Blotting检测并验证转导了PX458-gBCL11B的T细胞中BCL11B蛋白表达水平,以进一步确认BCL11B蛋白是否缺失的图示,对照组为转导了PX458空载体(Mock)的T细胞。
图4为流式细胞结果散点图,其显示相对于Mock T细胞和NK细胞,本发明的ITNK细胞(即,PX458-gBCL11B转导的T细胞,图中以PAX458指示)同时高表达T细胞标志物CD3和NK细胞标志物CD56和NKp46。所有样本来源于同一PBMC样本,Mock T为PBMC通过Pan-T分选,所以存在7.2-7.8%的CD3-CD56+NKp46+的NK细胞杂群;PX458为Mock T经过PX458-gBCL11B转染获得,与Mock-T存在相同的7.6-7.8%的NK细胞亚群;NK细胞为PBMC通过NK细胞培养基培养纯化获得,所以存在少量10.4%的CD3+CD56+的NKT或γδT细胞杂群。
图5为流式细胞结果散点图(A)其显示脐带血来源的ITNK细胞(即,PX458-gBCL11B转导的T细胞,图中以PAX458指示)相对于Mock T细胞同时高表达T细胞标志物CD3和NK细胞标志物NKp46、CD56、NKp30和NKp44,以及相应的细胞百分比统计图(B)。
图6为流式细胞结果散点图(A)其显示外周血来源的ITNK细胞(即,PX458-gBCL11B转导的T细胞,图中以PAX458指示)相对于Mock T细胞同时高表达T细胞标志物CD3和NK细胞标志物NKp46、CD56、NKp30和NKp44,以及相应的细胞百分比统计图(B)。
图7是Mock T细胞、NK细胞和ITNK细胞(即,PX458-gBCL11B转导的T细胞,图中以PAX458指示)的透射电镜图,其显示:与T细胞相比,ITNK细胞的核质比较低;其中,1指示核;2指示线粒体;3指示内质网;4指示粒;标尺,左图为2μm,右图为500nm。
图8显示PX458-gBCL11B转导的脐带血、外周血来源的T细胞(即,ITNK细胞)的CD4+、CD8+、CD3+CD4-CD8-T细胞亚群中NK受体表达,其中,NKp46在CD8+T细胞中表达明显高于CD4+T细胞;n=6,表示试验为6个独立健康供体的重复;***P≤0.001,配对t检验。
图9显示PX458-gBCL11转导的T细胞的流式细胞术分析,并将CD4+、CD8+和CD4-CD8-亚群中的CD56+细胞分选并进行DNA测序分析,进一步证实了ITNK细胞中的BCL11B位点被敲除。
图10显示TCRβ多样性测序,所有TCRβ链序列轨迹变量在同一来源的T细胞和ITNK细胞中具有相同的多样性。
图11显示TCRα多样性测序,所有TCRα链序列轨迹变量在同一来源的T细胞和ITNK细胞中具有相同的多样性。
图12是质谱流式聚类分析t-SEN点密度图,(A)显示分别来源于脐带血和外周血的CD45+单核细胞,分为进行转导PX458空载体(Mock-T)、转导PX458-gBCL11B(PX458-T)和转导了PX458-gBCL11B后经过K562细胞24小时活化(激活的PX458-T)三个实验组的t-SEN点密度;(B-C)分别展示脐带血(CB)、成体外周血(PBMC)来源的Mock-T和敲除BCL11B的T细胞(BCL11B-KO T)、是否经过激活的敲除BCL11B的T细胞(BCL11B-KO T)和(ActivatedBCL11B-KO T)之间的分群差异和过度转变情况(箭头)。
图13是脐带血和外周血CD45+细胞融合的t-SEN彩色富集簇图;ITNK细胞按指示标记。t-SEN图上标记物CD3、CD4、CD8、γδTCR、CD56、NKp46、NKp30、NKp44和CD11c的标准化表达使细胞着色。
图14是本发明ITNK细胞的免疫表型分析-脐带血和外周血CD45+细胞融合的t-SEN彩色富集簇图;其中,(A)显示NKG2D和CD161标记物表达量,(B)显示CD25、CD127、CD16、KIRDL2、KIRDL 3和NKG2A标志物表达量,以及(C)显示免疫检查点标记物PD-1、CTLA-4、FOXP3和TIM-3的表达量。
图15是根据脐带血T细胞的免疫细胞亚群分组的频率,ITNK细胞可由CD4+、CD8+和γδTCR+T细胞分化而来,所有ITNK亚型均可被HLA阴性细胞(K562)激活。
图16是根据外周血T细胞的免疫细胞亚群分组的频率,ITNK细胞可由CD4+、CD8+和γδTCR+ T细胞分化而来,所有ITNK亚型均可被HLA阴性细胞(K562)激活。
图17显示质谱流式热图分析结果,其显示了每个免疫细胞亚群的标志物表达情况。
图18显示用于RNA-Seq的ITNK细胞分选。分选脐带血或成体外周血中CD3+ T、CD3-NKp46+ NK、CD3+NKp46+ CB-ITNK和PBMC-ITNK用于RNA测序和atac测序。Mock-T(n=6)、ITNK(n=6)和NK细胞(n=4)的分选细胞纯度分别为95.3±3.61%、92.41±2.6%和92.88±2.06%。
图19是RNA测序-细胞亚群基因表达数据的主成分分析。
图20是RNA测序-KEGG富集途径分析ITNK细胞相对于T细胞的基因上调情况(截止:绝对对数2倍,变化≥1;调整P值≤0.05)。
图21是RNA测序-KEGG富集途径分析ITNK细胞相对于NK细胞的基因上调情况(截止:绝对对数2倍,变化≥1;调整P值≤0.05)。
图22是RNA-Seq分层聚类热图,其中,左图显示T、ITNK、NK细胞基因转录表达的差异(log2绝对倍数变化≥1;调整后P值≤0.05),右图是通过RNA-seq分析筛选出的基因在T细胞、ITNK细胞和NK细胞中差异表达的热点图;与T细胞相比,ITNK细胞中NK信号基因表达上调,TCF1和LEF1基因表达下调(log2绝对倍数变化≥1;调整后P值≤0.05)。
图23是ITNK细胞的免疫表型动态流式分析图;通过流式细胞技术,分析在人T细胞中敲除BCL11B后的第0、5、10、15、20天,检测CD3+CD4+、CD3+CD8+亚群中NKp30和NKp46阳性亚群的比例变化;数据代表了三个实验;BCL11B敲除后的第5天开始检测到NKp46,第10-15天稳定。
图24(A)是Sc-RNA seq分析结果的t-SNE点图,上图表示D0-D20的细胞分布图,下图表示PX458-gBCL11B基因转导T细胞敲除BCL11B后D0(2263)、D5(1565)、D10(498)、D15(204)、D20(418)天的4948个细胞聚类分布图。4948个细胞通过聚类为11个细胞亚群,ITNK细胞主要富集在(红色)圆圈标记的亚群;(B)通过t-SNE点图表示检测的4948个细胞(11个亚群)中NK细胞标志物表达的情况;(C)通过t-SNE点图表示检测的4948个细胞(11个亚群)中T细胞标志物、NK细胞标志物、免疫检查点、转录因子、凋亡基因相关基因的表达情况。
图25(A)KEGG信号通路分析,其显示NK细胞毒性基因在ITNK细胞中高表达;(B)小提琴图显示了不同亚群中NK细胞相关的KAR和KIR基因的表达谱;(C)小提琴图显示了与T细胞和NK细胞发育相关基因的表达谱。NK信号基因(ID2,TBX21)、NOTCH相关基因(MXI1,ZMIZ1,RBPJ)、AP-1相关基因(FOS,JUN,JUNB,JUND)在ITNK细胞中表达上调。
图26(A)为从亚群5(CD8+T)、亚群0(早期CD8+ITNK)和亚群1(晚期CD8+ITNK)的单个细胞的无监督轨迹分析显示CD8+T细胞向CD8+ITNK细胞的逐步过渡;(B)从亚群4(CD4+T)、亚群5(早期CD4+ITNK)和亚群7(晚期CD4+ITNK)的单个细胞的无监督轨迹分析显示CD4+T细胞向CD4+ITNK细胞的逐步过渡。
图27(A)为显示NK相关转录因子ID2和TBX21在ITNK细胞中表达水平上调的条形图;(B)为免疫细胞裂解液中TBX21和ID2的免疫印迹(Western Blot)分析,其中,左泳道为NK细胞,中泳道为ITNK细胞,右泳道为T细胞,并且β-Tublin作为内部参考。
图28为显示通过Elisa实验,检测T细胞和ITNK细胞分别经过anti-NKp30、anti-NKp46和anti-CD3/CD28抗体(5ug/ml)刺激后的IFNγ分泌量的柱状图;其中,数据来自三个独立供体的样本;数据以平均值±SD表示;**P≤0.01,***P≤0.001;配对t测试。
图29显示经过K562细胞刺激后,T细胞、ITNK细胞和NK细胞的细胞因子分泌情况;具体地,将T、ITNK和NK细胞分别以E(效应子):T(靶标)比1:1和K562细胞,在37℃下孵育18小时;取上清液,用多重免疫法(multiplex immunoassay)测定细胞因子(CSF2、CCL4、IFNγ、CCL3、IL13、IL2、TNF、CX3CL1、IL8、IL10、IL23、IL7、IL4、IL5、CXCL11、CCL20、IL6、IL17A、IL21、IL12、IL1β)浓度;值表示为3个不同供体的平均值±SD。
图30显示ITNK细胞对HLA阴性K562细胞(A)、HLA阳性Hela细胞(B)、HLA阳性A549细胞(C)和HLA阳性的NALM-6细胞(D)的特异性细胞毒性百分比,其中,数据以均数±标准差表示;**P≤0.01;非配对t检验。
图31显示免疫印迹法测定K562细胞刺激6小时后,免疫细胞裂解液中Fyn、PLC-g2、Syk、Erk1/2和mTOR的蛋白和磷酸化水平,其中,左边三泳道为NK细胞,中间三泳道为ITNK细胞,右边三泳道为T细胞,以BCL11B作为基因编辑对照,以GAPDH作为上样对照。
图32(A)为检测ITNK细胞体内杀伤肿瘤细胞试验的示意图;(B-C)显示利用体内生物荧光成像技术,对特定时间点的实验小鼠荧光素酶活性的总通量进行定量分析(每组5只小鼠),结果为平均值±SD,**P≤0.01,未配对t检验;(D)为PBS(n=10)、Mock T(n=15)、ITNK(n=15)、NK细胞(n=5)处理K562荷瘤小鼠的生存时间统计图;(E)显示第7天和第10天对Hela荷瘤小鼠分别进行PBS、Mock T、ITNK和NK细胞治疗,并于指定的时间点检测肿瘤大小(每组5只小鼠),数据以均数±标准差表示;***P≤0.001;非配对t检验。
图33显示ITNK细胞移植到缺失T、B、NK细胞的免疫缺陷小鼠NSI品系后其在小鼠体内的分布和维持情况;其中,(A上)为向NSI小鼠注射ITNK细胞和检测实验示意图,其显示ITNK在第1天、第7天、第14天、第21天和第6个月分别进行短期和长期的分析(每组n=3);(A下)显示了代表性的流式细胞术分析的CD3+T细胞中ITNK细胞的百分比;(B)为小鼠外周血(PB)、骨髓(BM)、脾脏、肝脏和肺中ITNK细胞的动态分布图,其显示在注射ITNK细胞6个月后检测不到T细胞和ITNK细胞。
具体实施方式
为更进一步阐述本发明所采取的技术手段及其效果,以下结合附图并通过具体实施方式来进一步说明本发明的技术方案,但本发明并非局限在实施例范围内。
除非另有说明,否则在这些实施例中阐述的部件和步骤的相对布置、数字表达式和数值不构成对本发明的限制。对于本领域普通技术人员已知的技术、方法和设备可能不作详细讨论,但在适当情况下,技术、方法和设备应当被视为本说明的一部分。
实施例1本发明的重编程的自然杀伤(ITNK)细胞的制备
基因敲除质粒载体构建
根据CRISP/CAS9靶位点的选择规则:GN19NGG,GN19是靶位点,N最好仍是G,靶位点可以在反义链上(即,在正义链上的序列顺序为:CCN N19C),选择了以下靶点序列并分别设计了正向(F)、反向(R)引物作为guideRNA(gRNA),将gRNA退火、连接入酶切好的PX458载体,构建了PX458-gBCL11B载体(如图1)。在293T细胞系中转染PX458-gBCL11B,并挑取单克隆,通过基因测序检测其中BCL11B敲除靶点的碱基缺失、错位等敲除情况(见图2),并统计计算敲除效率,如下表1。
表1、BCL11B靶点序列及其对应的gRNA列表
根据上述表1的敲除效率情况,选择敲除第二、第三外显子的gRNA基因敲除质粒载体,用于下一步实验。本申请优选在第二外显子、第三外显子中进行BCL11B基因敲除,利用第二外显子敲除效率最低的第一对gRNA和第二对gRNA的混合物,敲除效率最高的第三对gRNA,第三外显子敲除效率最低的第三对gRNA对应的基因敲除质粒以及它们的混合物均能将T细胞重编程获得了本发明的免疫杀伤淋巴细胞。在本实施例中,采用SEQ ID NO:5和SEQID NO:6、SEQ ID NO:50和SEQ ID NO:51的gRNA分别构建BCL11B基因敲除质粒并将其混合,用于下一步实验。
T细胞的分选和激活
采用以下方法进行T细胞的分选和激活:
(1)分别将包含人成熟T细胞的外周血和脐带血血液以300×g离心10分钟,收集血浆,在56℃下热灭活30分钟;
(2)将沉淀的颗粒状血细胞用0.9%NaCl悬浮,通过Ficoll密度梯度离心分离外周血单核细胞(PBMC);
(3)通过MACS Pan T分离试剂盒(Miltenyi Biotec,Bergisch Gladbach,Germany)阴性分选,从血液如外周血、脐带血等富集全部T细胞(Pan T)
以上(1)-(3)为从外周血和脐带血血液中分离人成熟T细胞的步骤,需要说明的是,其它T细胞来源亦可,如多能干细胞、造血干细胞定向诱导分化等。所有来源的T细胞均利用T细胞活化试剂盒(T cell activation kit(Miltenyi Biotec)),使用涂有抗人CD3、抗人CD28抗体和抗人CD2的磁珠与T细胞以1:2混合孵育激活(细胞密度:2.5×106个细胞/ml,培养基:T551-H3(Takara,Japan)培养基,含有5%自体血浆,hIL2(100IU/ml),硫酸庆大霉素(20μg/ml),10mm HEPES,2mm谷氨酰胺和1%青霉素/链霉素),活化24-48小时后,将T细胞从抗生物素MACS iBead TM颗粒中洗脱,备用。
诱导重编程
(1)通过电转(T-023,LONZA Amaxa Nucleofector,Lonza),将CRISP/CAS9敲除载体PX458-gBCL11B转导入上述激活后的T细胞;
(2)12小时后,将PX458-gBCL11B转导的T细胞(简称PX458-T)离心,并用T551-H3(Takara,Japan)培养基(含有5%自体血浆或胎牛血清(FBS),500IU/ml hIL2和硫酸庆大霉素(20μg/ml))培养;
(3)随后每3天更换新鲜培养基,保持细胞密度在0.5-1×106个细胞/ml范围内,直至电转后第14天。
(4)通过基因测序,检测并验证转导了PX458-gBCL11B的T细胞的BCL11B的第二外显子、第三外显子是否被敲除,如位点诱导插入或缺失等,对照组为转导了PX458空载体(Mock)的T细胞;
(5)通过Western Blotting,检测并验证转导了PX458-gBCL11B的T细胞中BCL11B蛋白表达水平,以进一步确认BCL11B蛋白的缺失,对照组为转导了PX458空载体(Mock)的T细胞,Western Blotting结果见图3。
重编程细胞的表型鉴定
如上,电转T细胞14天后,所得细胞中有19.5-68.7%既表达T细胞标志物如CD3,也表达NK细胞标志物如NKp46、CD56、NKp30和NKp44,则确定获得了本发明的人ITNK细胞。NK细胞只表达NK细胞标志物如NKp46、CD56,但不表达T细胞标志物如CD3。电转空载体的T细胞表达T细胞标志物如CD3,但不表达NK细胞标志物。T细胞、NK细胞和ITNK细胞的各细胞标志物的表达情况如图4-6所示,它们的表型差异也归纳于以下表2。
表2、ITNK细胞与T细胞、NK细胞的表型差异
此外,通过共聚焦显微镜观察显示,由T细胞重编程而来的ITNK细胞具有区别于T细胞的细胞形态,其形态与NK细胞类似,细胞核(相对于T细胞细胞核占据细胞整体体积)较小,细胞内基质较多,颗粒增大,内质网丰富,高蛋白合成活性,表明重编程后的ITNK细胞为免疫杀伤淋巴细胞。T细胞、NK细胞和ITNK细胞的透射电镜图如图7所示。
此外,发明人还比较了脐带血来源和外周血来源的BCL11B缺失的T细胞亚群中这些NK标志物的表达谱,发现CD8+NKp46+和CD8+CD56+细胞的百分比显着高于CD4+NKp46+和CD4+CD56+细胞,表明NKp46+CD3+ITNK主要来源于CD8+T细胞(见图8)。与CD8+T细胞不同,CD4+T细胞在失去BCL11B后表达NKp30但不表达NKp46(见图8B)。
CD4-CD8-NKp46+亚群表达了“TCRγδ”,为γδTCR+ITNK细胞(见图9)。通过DNA测序进一步验证CD4+、CD8+和γδTCR+T细胞中的BCL11B缺失(见图9)。
实施例2本发明ITNK细胞的来源鉴定
TCRαβ测序:通过人TCRαβ分析试剂盒,将同一供者来源的T细胞和实施例1所得ITNK细胞进行RNA提取和CDR3区域靶向扩增,获得TCR RNA。利用Hiseq4000平台,对TCR RNA进行测序,获得TCR文库。使用MiXCR(ref)进行聚类组合分析。通过MiXCR克隆导出指令,以“—链”参数导出TCRαβ克隆类型。通过TCR测序,比较同一供者来源的T细胞和ITNK细胞的TCR克隆的多样性,发现TCR克隆多样性一致(见图10和11),由此确定所得ITNK细胞是T细胞缺失BCL11B后重编程而来,并保持了T细胞的TCR多样性,而不是人T细胞中的特殊、未知小亚群扩增而来的。
实施例3本发明ITNK细胞的单细胞免疫表型鉴定
通过质谱流式细胞技术(Mass Cytometry,CyTOF),分别对实施例1所得ITNK细胞进行单细胞免疫表型分析,对照组为转导了空载体的T细胞。
质谱仪样品的制备和预处理:将来自培养悬浮液的细胞离心,用含有0.5%BSA和0.02%NaN 3的PBS重悬,并在室温下用抗人CD16/32的单克隆抗体孵育10分钟以阻断Fc受体。随后,加入针对细胞表面分子的金属标记的抗体混合物,并在冰上进一步孵育20分钟。抗体为预耦合的抗体(Fluidigm)或使用质谱流式耦合试剂盒(Fluidigm)并根据说明书进行内部耦合。向细胞中加入5mM顺铂(cisplatin),在FBS(Fluidigm)中在冰上孵育染色1分钟。在用固定/透化缓冲液(Thermo Fisher)处理后,将细胞与金属标记抗体混合孵育以标记细胞内蛋白质。清洗细胞后,用1mL的1:4000稀释的191/193Ir DNA嵌入剂(Fluidigm)(嵌入剂用含有1.6%多聚甲醛(EMS)的PBS稀释)染色,并储存在4℃。检测前,将细胞用含有0.5%BSA和0.02%NaN 3的PBS洗涤一次,用ddH2O洗涤一次,然后用超纯水(ddH2O)将细胞重悬和稀释至约106个细胞/毫升。随后,利用CyTOF2设备(Fluidigm)以<400事件/秒的事件速率检测和收集细胞样品数据。
通过PhenoGraph聚类算法,根据40个标记物的细胞免疫表型差异进行聚类分析,将脐带血来源的ITNK细胞(下文也称CB-ITNK)、外周血来源的ITNK细胞(下文也称为PBMC-ITNK)和Mock-T细胞整合并分类为39个亚群,如图12、13、14、15、16和17。由图12可知,K562细胞刺激前后的PX458 T与Mock-T之间分离,几乎不存在重叠,表明PX458T与Mock-T之间差异显著;而经过K562细胞刺激前后的PX458 T细胞之间存在明显的重叠,且激活后的PX458-T细胞衍生了更多新的亚群。
根据质谱流式细胞标记物表达异质性分析结果,本发明的ITNK细胞包括NO.33的CD3阴性细胞亚群、NO.5-10的CD4+细胞亚群、NO.20-22和26-28的CD8+细胞亚群以及NO.23-24的TCRγδ+细胞亚群,且均表达NK相关标志物如CD56、NKp30、NKp44、NKp46或CD11C等,TCRγδ+ITNK相对于γδT细胞,NKp46、NKp30和NKp44三个标志物均为高表达,即(NKp46highNKp30high NKp44high)(如图13和14A)。本发明的ITNK细胞区别于常规的NK细胞,因为本发明的ITNK细胞不表达CD127、CD16、NKG2A和KIR2DL2(如图14B)。而且,本发明的ITNK细胞低表达免疫抑制检查点PD-1、CTLA-4、FOXP3(如图14C),免疫抑制检查点的高表达会诱导免疫细胞形成低功能、衰竭等免疫抑制状态,由此提示本发明的ITNK细胞具有强免疫效应,且不容易被肿瘤等免疫抑制微环境所抑制。
此外,在脐带血来源的ITNK细胞中,如图15的柱状图清晰地显示了各种ITNK细胞在CD45+造血细胞中所占的百分比,以及刺激后从静止ITNK细胞向效应细胞的动态转变。如图16所示,成年人外周血来源的ITNK细胞经刺激后从静息状态向效应状态的动态转变也与脐带血来源的ITNK相同。如图17的质谱流式热图(heatmap)显示了激活前后ITNK细胞的免疫表型动态变化,激活后CD25表达升高。综上所述,ITNK激活后,仍然保留NK细胞激活受体和T细胞标志物的表达。
实施例4本发明ITNK细胞的RNA-Seq转录谱分析
为了研究ITNK细胞的全部基因表达谱,发明人对来自于4个脐带血样品和3个成体外周血样品的T和ITNK细胞,以及来自于2个脐带血样品和2个成体外周血样品的NK细胞进行了RNA测序分析。分选操作如下:通过流式细胞仪Canto、FACS Fortessa(BD)、FACSAriaII等进行流式细胞分析或分选。细胞表面受体标记,将细胞与抗体用50μl流式缓冲液(含2%FBS的PBS溶液)混合,4度避光孵育30分钟;细胞胞内标记,细胞利用Foxp3/转录因子染色缓冲液(eBioscience)进行通透性处理,洗脱缓冲液后,用鼠或兔血清阻断,与抗体4度避光孵育30分钟,利用流式缓冲液冲洗一遍后重悬,备用进行流式细胞分析或分选。细胞分选策略和分选纯度验证(如图18)。
采用主成分分析(PCA)对18个样本的RNA测序结果进行相似性评价,发现从转录组分析,ITNK不同于T细胞和NK细胞(如图19)。与T细胞相比,增加776个基因(数据未显示),包括NK特异性转录因子(如ID2、TBX21、NFIL3、IRF8)、激活和抑制NK细胞受体/蛋白(如IL2RB、IFNG、PRF1、GZMB、TNFRSF4、NCR1、NCR2、PLCG2)、组蛋白基因(HIST1H1D、HIST1H2AC/D/E/G/M、HIST2H2A3/4)(如图22和20);相反,与T细胞相比,ITNK细胞中有592个基因如TCF-1/TCF-7、LEF-1、IL-7R、MYC、PD-L1、FOXP3等被下调(如表3)。与NK细胞相比,ITNK中666个基因表达增加(数据未显示),其中大多数基因在T细胞识别和TCR信号转导(CD3、CD4、CD8、CD40LG)中富集(图21)。有趣的是,与NK细胞相比,ITNK中KIR基因KIR2DL1、KIR2DL3、KIR3DL1和KIR3DL2表达下调(如表4),而KIR2DL1、KIR2DL3、KIR3DL1和KIR3DL2为NK细胞抑制性受体,介导免疫细胞的抑制作用,而其低表达则表示ITNK细胞具有对免疫抑制微环境的抵抗作用。全转录组测序分析结果显示,NK细胞标志性基因IL2RB、ID2、NFIL3等在ITNK细胞中上调表达(图22右)。
表3、ITNK细胞相对于NK细胞的相关基因表达
表4、ITNK细胞相对于NK细胞的相关基因表达
实施例5本发明ITNK细胞的单细胞转录组测序分析
流式细胞术显示CD8+CD3+NKp46+ITNK和CD4+CD3+NKp30+ITNK在敲除BCL11B后5天即出现(如图23)。为了进一步解释T细胞向ITNK重编程过程中的细胞命运转变,我们使用基于微孔的单细胞转录组测序(scRNA-seq)技术,研究了敲除BCL11B后不同时间点CD3+脐带血样品中T和ITNK细胞在单细胞水平上的基因表达谱。
所有实验组共计检测分析约5000个细胞。scRNA-seq检测不同时间点组细胞样本,平均每个细胞检测2000-4000个基因,在所有细胞中共检测到20000个人类基因。在转录谱的t-SNE(t-distributed random neighbor-embedded)分析中,将细胞投射到二维上,为ITNK细胞重编程过程中的细胞命运转变提供了可视化的表现方式。无偏t-SEN分析结果显示,从敲除后第0天到第20天的细胞可聚类为11个亚群(如图24)。根据T细胞和NK细胞的标志性基因表达情况,确定ITNK细胞主要集中在亚群6(CD4+ITNK)、亚群1(CD8+ITNK)和亚群10(γδTCR+ITNK)(如图24),而这些亚群与BCL11B缺失表达亚群完全重合,进一步说明ITNK细胞是由T细胞中敲除BCL11B重编程而来。KEGG富集分析表明,ITNK细胞特异性高表达NK标记基因及其相关基因(如图25)。由图24C、图25C可知,人ITNK细胞中NOTCH1、NOTCH2、ZMIZ1(NOTCH1辅助因子)、RBPJ(NOTCH下游转录因子)均上调,提示NOTCH信号通路在ITNK细胞重编程中的发挥作用。FOS、JUN、JUNB,三个AP-1转录因子的亚基在ITNK重编程早期低表达,而重编程晚期逐渐上调表达(如图25C)。可知NOTCH信号和AP-1信号在ITNK重编后上调。T细胞和ITNK细胞在t-SNE点图中紧密聚集,说明T细胞向NK细胞的转变几乎是同步的。通过对CD8+T(亚群5)、早期CD8+ITNK(亚群0)和晚期CD8+ITNK(亚群1)的NK标志性基因的轨迹分析,可以看出CD8+T细胞向CD8+ITNK的逐步过渡(如图26A)。同样,CD4+T细胞和ITNK细胞NK标志性基因的轨迹分析也显示了T细胞向ITNK细胞的逐步过渡(图26B)。与(图23)ITNK细胞的免疫表型动态流式分析结果一致,T细胞敲除BCL11B后第五天开始重编程为ITNK细胞。我们发现转录因子基因(TBX2、ID2等)在T细胞向ITNK细胞重编程过程中表达明显上调,并通过免疫印迹进一步进行了验证(如图27)。
实施例6本发明ITNK细胞可体外识别和杀伤MHCI阳性/阴性的肿瘤细胞
为了确定本发明的ITNK细胞上表达的NK细胞受体(NCR)和T细胞受体(TCR)是否有功能,我们分别利用抗NKp30、抗NKp46和抗CD3/CD28的单克隆抗体刺激ITNK细胞,发现:抗NKp30、抗NKp46抗体刺激后,ITNK细胞的干扰素(IFN)分泌增加,而对照组T细胞的不增加(如图28);用抗CD3/CD28抗体刺激后,ITNK细胞的干扰素分泌增加,而对照组T细胞的不增加(如图28)。这表明,ITNK细胞中的NCR和TCR是功能性的。
与NK细胞类似,本发明的ITNK细胞可分泌各种细胞因子,包括GM-CSF、IFN和TNF(如图29),且可识别杀伤MHC-I阴性的K562细胞(如图30A)。此外,ITNK细胞能有效杀死Hela和A549细胞(如图30B-C),这两种细胞都是高表达NK激活型受体的配体且MHC I为阳性;如表2,由于ITNK细胞低表达介导免疫抑制作用的NK细胞KIR受体(KIR2DL1、KIR2DL3、KIR3DL1和KIR3DL2),所以ITNK细胞对肿瘤的杀伤效果比NK细胞更好。但是,NALM-6不表达NCR配体,且高表达MHC-I分子,ITNK细胞与NK细胞对NALM-6无显著杀伤(如图30D)。然后,发明人利用K562细胞分别刺激ITNK、NK和T细胞,发现:ITNK和NK细胞中的磷酸化Fyn、PLC-γ2、Syk、Erk和m-TOR表达水平相似,但高于T细胞(如图31)。这些结果表明,ITNK细胞在NCR活化、细胞因子分泌、细胞毒性和信号通路等方面具有相似的NK细胞功能。
实施例8本发明的ITNK细胞可体内抑制肿瘤生长
发明人还评估了本发明的ITNK细胞是否能够抑制异种移植瘤的生长。具体地,将标记有荧光素酶的K562细胞植入NSI小鼠,构建K562荷瘤小鼠模型,然后单次注入ITNK、NK或T细胞(图32A)。于特定时间点,通过活体成像设备检测K562在小鼠体内的存活状况。与注射T细胞(阴性对照)、PBS(空白对照)组相比,ITNK细胞和NK细胞处理的实验小鼠在输注28天后K562肿瘤负荷显著减少(图32B和32C),存活时间更长(图32D)。此外,发明人还用Hela细胞移植入NSI小鼠,并分别用ITNK、NK或T细胞治疗Hela异种移植小鼠,结果显示,用ITNK细胞治疗的荷瘤小鼠的Hela肿瘤生长速度显著慢于NK、T细胞或PBS处理组(图32E)。由此可见,本发明的ITNK细胞是体内肿瘤细胞的有效杀手,可以阻止肿瘤进展。
实施例9本发明的ITNK细胞体内安全性评估
为了验证ITNK细胞在体内的分布和维持能力。我们将ITNK细胞移植到缺失T、B、NK细胞的免疫缺陷小鼠NSI品系体内,并检测移植1、7、14、21和180后,外周血测量外周血与(PB)、脾脏(SP)、骨髓(BM)、肝脏(liver)和肺(lung)中ITNK细胞的百分比(图33A-B)。ITNK细胞比例在移植后21天达到最高点,其后逐渐减少,6个月后无法检测到(图33B)。由图33B可知,ITNK细胞体内维持能力相对于T细胞更好。我们始终没有观察到ITNK细胞攻击宿主或无限制扩增的情况。
为了评估PX458-gBCL11B可能引起的靶外突变,我们对PX458-gBCL11B电穿孔T细胞进行了高覆盖率的全基因组测序。与野生型T细胞相比,我们从两个独立的实验中发现,PX458-gBCL11B编辑的T细胞中,由核酸酶引起的脱靶突变非常少。
申请人声明,本发明通过上述实施例来说明本发明的详细方法,但本发明并不局限于上述详细方法,即不意味着本发明必须依赖上述详细方法才能实施。所属技术领域的技术人员应该明了,对本发明的任何改进,对本发明产品各原料的等效替换及辅助成分的添加、具体方式的选择等,均落在本发明的保护范围和公开范围之内。
序列表
<110> 英基生物医药(香港)有限公司
<120> 一种工程化人体免疫细胞、其制备方法及应用
<130> PY2019
<160> 51
<170> PatentIn version 3.3
<210> 1
<211> 20
<212> DNA
<213> 人类
<400> 1
gaccctgacc tgctcacctg 20
<210> 2
<211> 24
<212> DNA
<213> 人工序列
<220>
<223> 针对第二外显子靶点序列的正向引物
<400> 2
caccgaccct gacctgctca cctg 24
<210> 3
<211> 24
<212> DNA
<213> 人工序列
<220>
<223> 针对第二外显子靶点序列的反向引物
<400> 3
aaaccaggtg agcaggtcag ggtc 24
<210> 4
<211> 20
<212> DNA
<213> 人类
<400> 4
gaagcagtgt ggcggcagct 20
<210> 5
<211> 24
<212> DNA
<213> 人工序列
<220>
<223> 针对第二外显子靶点序列的正向引物
<400> 5
caccgaagca gtgtggcggc agct 24
<210> 6
<211> 24
<212> DNA
<213> 人工序列
<220>
<223> 针对第二外显子靶点序列的反向引物
<400> 6
aaacagctgc cgccacactg cttc 24
<210> 7
<211> 20
<212> DNA
<213> 人类
<400> 7
caggtggtca tcttcgtcgg 20
<210> 8
<211> 24
<212> DNA
<213> 人工序列
<220>
<223> 针对第二外显子靶点序列的正向引物
<400> 8
cacccaggtg gtcatcttcg tcgg 24
<210> 9
<211> 24
<212> DNA
<213> 人工序列
<220>
<223> 针对第二外显子靶点序列的反向引物
<400> 9
aaacccgacg aagatgacca cctg 24
<210> 10
<211> 19
<212> DNA
<213> 人类
<400> 10
gcaggtggtc atcttcgtc 19
<210> 11
<211> 23
<212> DNA
<213> 人工序列
<220>
<223> 针对第二外显子靶点序列的正向引物
<400> 11
caccgcaggt ggtcatcttc gtc 23
<210> 12
<211> 23
<212> DNA
<213> 人工序列
<220>
<223> 针对第二外显子靶点序列的反向引物
<400> 12
aaaccgacga agatgaccac ctg 23
<210> 13
<211> 20
<212> DNA
<213> 人类
<400> 13
gctcaggaaa gtgtccgagc 20
<210> 14
<211> 24
<212> DNA
<213> 人工序列
<220>
<223> 针对第二外显子靶点序列的正向引物
<400> 14
caccgctcag gaaagtgtcc gagc 24
<210> 15
<211> 23
<212> DNA
<213> 人工序列
<220>
<223> 针对第二外显子靶点序列的反向引物
<400> 15
aaacgctcgg acactttcct gag 23
<210> 16
<211> 20
<212> DNA
<213> 人类
<400> 16
gagtcccgtc acccgagacc 20
<210> 17
<211> 24
<212> DNA
<213> 人工序列
<220>
<223> 针对第三外显子靶点序列的正向引物
<400> 17
caccgagtcc cgtcacccga gacc 24
<210> 18
<211> 23
<212> DNA
<213> 人工序列
<220>
<223> 针对第三外显子靶点序列的反向引物
<400> 18
aaacggtctc gggtgacggg act 23
<210> 19
<211> 20
<212> DNA
<213> 人类
<400> 19
gaagtgatca cggatgagtg 20
<210> 20
<211> 24
<212> DNA
<213> 人工序列
<220>
<223> 针对第三外显子靶点序列的正向引物
<400> 20
caccgaagtg atcacggatg agtg 24
<210> 21
<211> 23
<212> DNA
<213> 人工序列
<220>
<223> 针对第三外显子靶点序列的反向引物
<400> 21
aaaccactca tccgtgatca ctt 23
<210> 22
<211> 20
<212> DNA
<213> 人类
<400> 22
ggtgacggga ctcagggtga 20
<210> 23
<211> 24
<212> DNA
<213> 人工序列
<220>
<223> 针对第三外显子靶点序列的正向引物
<400> 23
caccggtgac gggactcagg gtga 24
<210> 24
<211> 23
<212> DNA
<213> 人工序列
<220>
<223> 针对第三外显子靶点序列的反向引物
<400> 24
aaactcaccc tgagtcccgt cac 23
<210> 25
<211> 20
<212> DNA
<213> 人类
<400> 25
tgcagcgcgc gcccggtctc 20
<210> 26
<211> 24
<212> DNA
<213> 人工序列
<220>
<223> 针对第三外显子靶点序列的正向引物
<400> 26
cacctgcagc gcgcgcccgg tctc 24
<210> 27
<211> 24
<212> DNA
<213> 人工序列
<220>
<223> 针对第三外显子靶点序列的反向引物
<400> 27
aaacgagacc gggcgcgcgc tgca 24
<210> 28
<211> 20
<212> DNA
<213> 人类
<400> 28
cacgagagcg acccgtcgct 20
<210> 29
<211> 24
<212> DNA
<213> 人工序列
<220>
<223> 针对第四外显子靶点序列的正向引物
<400> 29
cacccacgag agcgacccgt cgct 24
<210> 30
<211> 24
<212> DNA
<213> 人工序列
<220>
<223> 针对第四外显子靶点序列的反向引物
<400> 30
aaacagcgac gggtcgctct cgtg 24
<210> 31
<211> 20
<212> DNA
<213> 人类
<400> 31
gcgacgggtc gctctcgtgg 20
<210> 32
<211> 24
<212> DNA
<213> 人工序列
<220>
<223> 针对第四外显子靶点序列的正向引物
<400> 32
caccgcgacg ggtcgctctc gtgg 24
<210> 33
<211> 23
<212> DNA
<213> 人工序列
<220>
<223> 针对第四外显子靶点序列的反向引物
<400> 33
aaacccacga gagcgacccg tcg 23
<210> 34
<211> 20
<212> DNA
<213> 人类
<400> 34
tccatgctga agctcgactc 20
<210> 35
<211> 24
<212> DNA
<213> 人工序列
<220>
<223> 针对第四外显子靶点序列的正向引物
<400> 35
cacctccatg ctgaagctcg actc 24
<210> 36
<211> 24
<212> DNA
<213> 人工序列
<220>
<223> 针对第四外显子靶点序列的反向引物
<400> 36
aaacgagtcg agcttcagca tgga 24
<210> 37
<211> 20
<212> DNA
<213> 人类
<400> 37
acgggtcgct ctcgtggtgg 20
<210> 38
<211> 24
<212> DNA
<213> 人工序列
<220>
<223> 针对第四外显子靶点序列的正向引物
<400> 38
caccacgggt cgctctcgtg gtgg 24
<210> 39
<211> 24
<212> DNA
<213> 人工序列
<220>
<223> 针对第四外显子靶点序列的反向引物
<400> 39
aaacccacca cgagagcgac ccgt 24
<210> 40
<211> 20
<212> DNA
<213> 人类
<400> 40
agccgcaacc gcgagaacgg 20
<210> 41
<211> 24
<212> DNA
<213> 人工序列
<220>
<223> 针对第四外显子靶点序列的正向引物
<400> 41
caccagccgc aaccgcgaga acgg 24
<210> 42
<211> 24
<212> DNA
<213> 人工序列
<220>
<223> 针对第四外显子靶点序列的反向引物
<400> 42
aaacccgttc tcgcggttgc ggct 24
<210> 43
<211> 20
<212> DNA
<213> 人类
<400> 43
gcaacttgac ggtgcaccgg 20
<210> 44
<211> 24
<212> DNA
<213> 人工序列
<220>
<223> 针对第四外显子靶点序列的正向引物
<400> 44
caccgcaact tgacggtgca ccgg 24
<210> 45
<211> 23
<212> DNA
<213> 人工序列
<220>
<223> 针对第四外显子靶点序列的反向引物
<400> 45
aaacccggtg caccgtcaag ttg 23
<210> 46
<211> 20
<212> DNA
<213> 人类
<400> 46
gagctgggcc gcccggggcc 20
<210> 47
<211> 24
<212> DNA
<213> 人工序列
<220>
<223> 针对第四外显子靶点序列的正向引物
<400> 47
caccgagctg ggccgcccgg ggcc 24
<210> 48
<211> 23
<212> DNA
<213> 人工序列
<220>
<223> 针对第四外显子靶点序列的反向引物
<400> 48
aaacggcccc gggcggccca gct 23
<210> 49
<211> 20
<212> DNA
<213> 人类
<400> 49
ggtcagacgg aggctccctt 20
<210> 50
<211> 24
<212> DNA
<213> 人工序列
<220>
<223> 针对第三外显子靶点序列的正向引物
<400> 50
caccggtcag acggaggctc cctt 24
<210> 51
<211> 24
<212> DNA
<213> 人工序列
<220>
<223> 针对第三外显子靶点序列的反向引物
<400> 51
aaacaaggga gcctccgtct gacc 24
Claims (19)
1.一种通过重编程人T细胞诱导而成的免疫杀伤淋巴细胞,其保留衍生其的人T细胞的标志物和功能并具有NK细胞的标志物和功能,其中,所述人T细胞的重编程涉及BCL11B基因的缺失。
2.根据权利要求1所述的细胞,其中,所述人T细胞为成熟人T细胞或含有成熟人T细胞的细胞群;
优选地,所述成熟人T细胞或含有成熟人T细胞的细胞群来源于人体脐带血或外周血;
优选地,所述成熟人T细胞或含有成熟人T细胞的细胞群来源于多能干细胞、胚胎干细胞或脐带血干细胞分化获得的成熟T细胞或细胞群。
3.根据权利要求1或2所述的细胞,其表达功能性的TCR、CD3和NKp30。
4.根据权利要求1-3任一项所述的细胞,其表达选自以下的NK细胞的标志物:CD11c、NKG2D和CD161;
优选地,其低表达或不表达PD-1、CTLA-4或FOXP3免疫抑制检查点;
优选地,其低表达或不表达NK相关标志物:CD127、CD16、KIRDL2、KIRDL3、NKG2A。
5.根据权利要求1-4任一项所述的新型免疫杀伤淋巴细胞,其中,相较于衍生其的T细胞,NOTCH表达上调。
6.根据权利要求1-5任一项所述的细胞,其中,相较于衍生其的T细胞,LEF1和TCF7转录因子表达下降,NOTCH、AP1、ID2、TBX21和NFIL3表达上升。
7.根据权利要求1-6任一项所述的细胞,其中,其TCR介导的信号转导增强;
优选地,相较于衍生其的T细胞,其与TCR介导的信号转导相关的基因CSF2、FOS、MAPK12、MAP3K8、IFNγ、NFKBIA、MAPK11、IL-10和TEC的表达上调;
优选地,相对于NK细胞,其T细胞识别和TCR信号转导增强;优选地,CD3、CD4、CD8、CD40LG的表达上调。
8.根据权利要求1-7任一项所述的细胞,其中,相较于衍生其的T细胞,其NK杀伤毒性相关信号转导增强;
优选地,相较于衍生其的T细胞,其与NK杀伤毒性相关信号转导相关的基因PRF1、CSF2、ICAM1、CD244、PLCG2、IFNG、FCER1G、GZMB、NCR2、NCR1、KIR2DL4和SYK的表达上调。
9.根据权利要求1-8任一项所述的细胞,其包括CD8+NKp46+NKp44+NKp30+、CD4+NKp30+和γδTCR+NKp46+NKp44+NKp30+T细胞亚群。
10.根据权利要求1-9任一项所述的细胞,其中,所述人T细胞为成熟人T细胞,并且重编程所述人成熟T细胞包括:
1)激活成熟人T细胞;
2)对步骤1)所得激活的成熟人T细胞实施BCL11B基因敲除;
3)将步骤2)所得细胞用T细胞培养基进行培养。
11.根据权利要求10所述的细胞,其中,步骤1)中,使用抗人CD3抗体、抗人CD28抗体和抗人CD2抗体进行激活;
优选地,使用抗人CD3抗体、抗人CD28抗体和抗人CD2抗体的磁珠与人成熟T细胞以1:2混合孵育激活T细胞。
12.根据权利要求10或11所述的细胞,其中,步骤2)中,使用CRISPR/CAS9技术进行BCL11B基因敲除;
优选地,所述基因敲除的靶点在BCL11B基因的第二外显子处;
优选地,所述基因敲除的靶点在BCL11B基因的第三外显子处。
13.根据权利要求10-12任一项所述的细胞,其中,步骤3)中,所述T细胞培养基包含IL-2;优选地,不与OP9-DL1进行共培养。
14.一种制备权利要求1-13任一项所述的细胞的方法,其包括:
1’)激活人T细胞;
2’)对步骤1’)所得激活的人T细胞实施BCL11B基因敲除;
3’)将步骤2’)所得细胞用T细胞培养基进行培养。
15.根据权利要求14所述的方法,其中,所述人T细胞为成熟人T细胞或含有成熟人T细胞的细胞群;
优选地,所述成熟人T细胞或含有成熟人T细胞的细胞群来源于人体脐带血或外周血;
优选地,所述成熟人T细胞或含有成熟人T细胞的细胞群来源于多能干细胞、胚胎干细胞或脐带血干细胞分化获得的成熟T细胞或细胞群。
16.根据权利要求14或15所述的方法,其中,步骤1’)中,使用抗人CD3抗体、抗人CD28抗体和抗人CD2抗体进行激活;
优选地,使用抗人CD3抗体、抗人CD28抗体和抗人CD2抗体的磁珠与人成熟T细胞以1:2混合孵育激活T细胞。
17.根据权利要求14-16任一项所述的方法,其中,步骤2’)中,使用CRISPR/CAS9技术进行BCL11B基因敲除;
优选地,在BCL11B基因的第二外显子处进行基因敲除;
优选地,在BCL11B基因的第三外显子处进行基因敲除。
18.根据权利要求14-17任一项所述的方法,其中,步骤3’)中,所述T细胞培养基包含IL-2;优选地,不与OP9-DL1进行共培养。
19.权利要求1-13任一项所述的细胞在制备治疗选自以下的疾病的药物中的用途:肿瘤、艾滋病和感染性疾病;优选地,所述感染性疾病为病毒感染性疾病。
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910945529.3A CN112574952A (zh) | 2019-09-30 | 2019-09-30 | 一种工程化人体免疫细胞、其制备方法及应用 |
AU2020359872A AU2020359872A1 (en) | 2019-09-30 | 2020-09-27 | Engineered human immune cells, preparation method and application thereof |
EP20871608.4A EP4039803A4 (en) | 2019-09-30 | 2020-09-27 | MANIPULATED HUMAN IMMUNE CELLS, METHOD OF PREPARATION AND CORRESPONDING APPLICATION |
US17/639,237 US20220325246A1 (en) | 2019-09-30 | 2020-09-27 | Engineered human immune cells, preparation method and application thereof |
PCT/CN2020/118104 WO2021063285A1 (zh) | 2019-09-30 | 2020-09-27 | 一种工程化人体免疫细胞、其制备方法及应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910945529.3A CN112574952A (zh) | 2019-09-30 | 2019-09-30 | 一种工程化人体免疫细胞、其制备方法及应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN112574952A true CN112574952A (zh) | 2021-03-30 |
Family
ID=75116910
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201910945529.3A Pending CN112574952A (zh) | 2019-09-30 | 2019-09-30 | 一种工程化人体免疫细胞、其制备方法及应用 |
Country Status (5)
Country | Link |
---|---|
US (1) | US20220325246A1 (zh) |
EP (1) | EP4039803A4 (zh) |
CN (1) | CN112574952A (zh) |
AU (1) | AU2020359872A1 (zh) |
WO (1) | WO2021063285A1 (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111849919A (zh) * | 2020-07-24 | 2020-10-30 | 英基生物医药(香港)有限公司 | 一种具有抗病毒活性的工程化免疫细胞及其构建方法和应用 |
CN114350608A (zh) * | 2022-01-27 | 2022-04-15 | 昭泰英基生物医药(香港)有限公司 | 一种诱导t细胞重编程为类nk细胞的组合物及其应用 |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112574952A (zh) * | 2019-09-30 | 2021-03-30 | 英基生物医药(香港)有限公司 | 一种工程化人体免疫细胞、其制备方法及应用 |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1556854A (zh) * | 2001-09-20 | 2004-12-22 | �Ƹ��� | 细胞的活化及扩增 |
US20120288484A1 (en) * | 2009-07-15 | 2012-11-15 | Genome Research Limited | Cells, compositions and methods |
CN111849919A (zh) * | 2020-07-24 | 2020-10-30 | 英基生物医药(香港)有限公司 | 一种具有抗病毒活性的工程化免疫细胞及其构建方法和应用 |
CN112048480A (zh) * | 2020-09-09 | 2020-12-08 | 广东昭泰体内生物医药科技有限公司 | 一种基于电转制备nk样细胞的方法 |
CN112063653A (zh) * | 2020-09-09 | 2020-12-11 | 广东昭泰体内生物医药科技有限公司 | 一种基于电转重编程质粒制备nk样细胞的方法 |
CN114269902A (zh) * | 2019-12-27 | 2022-04-01 | 昭泰英基生物医药(香港)有限公司 | 一种工程化免疫杀伤细胞、其制备方法及应用 |
US20220325246A1 (en) * | 2019-09-30 | 2022-10-13 | Zhaotai Immugene Biomedicine (Hong Kong) Limited | Engineered human immune cells, preparation method and application thereof |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111607569A (zh) * | 2020-06-01 | 2020-09-01 | 广东昭泰体内生物医药科技有限公司 | 一种基于CRISPR/Cas9重编程ITNK细胞的方法 |
-
2019
- 2019-09-30 CN CN201910945529.3A patent/CN112574952A/zh active Pending
-
2020
- 2020-09-27 US US17/639,237 patent/US20220325246A1/en active Pending
- 2020-09-27 EP EP20871608.4A patent/EP4039803A4/en active Pending
- 2020-09-27 WO PCT/CN2020/118104 patent/WO2021063285A1/zh unknown
- 2020-09-27 AU AU2020359872A patent/AU2020359872A1/en active Pending
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1556854A (zh) * | 2001-09-20 | 2004-12-22 | �Ƹ��� | 细胞的活化及扩增 |
US20120288484A1 (en) * | 2009-07-15 | 2012-11-15 | Genome Research Limited | Cells, compositions and methods |
US20220325246A1 (en) * | 2019-09-30 | 2022-10-13 | Zhaotai Immugene Biomedicine (Hong Kong) Limited | Engineered human immune cells, preparation method and application thereof |
CN114269902A (zh) * | 2019-12-27 | 2022-04-01 | 昭泰英基生物医药(香港)有限公司 | 一种工程化免疫杀伤细胞、其制备方法及应用 |
CN111849919A (zh) * | 2020-07-24 | 2020-10-30 | 英基生物医药(香港)有限公司 | 一种具有抗病毒活性的工程化免疫细胞及其构建方法和应用 |
CN112048480A (zh) * | 2020-09-09 | 2020-12-08 | 广东昭泰体内生物医药科技有限公司 | 一种基于电转制备nk样细胞的方法 |
CN112063653A (zh) * | 2020-09-09 | 2020-12-11 | 广东昭泰体内生物医药科技有限公司 | 一种基于电转重编程质粒制备nk样细胞的方法 |
Non-Patent Citations (2)
Title |
---|
LONG LI等: "An early T cell lineage commitment checkpoint dependent on the transcription factor bcl11b", 《SCIENCE》, vol. 329, no. 5987, 2 July 2010 (2010-07-02), pages 89 - 93, XP002600151, DOI: 10.1126/SCIENCE.1188989 * |
PENG LI等: "Reprogramming of T cells to Natural Killer-like cells upon BCL11B deletion", 《SCIENCE》, vol. 329, no. 5987, 10 June 2010 (2010-06-10), pages 85 - 89, XP002600150 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111849919A (zh) * | 2020-07-24 | 2020-10-30 | 英基生物医药(香港)有限公司 | 一种具有抗病毒活性的工程化免疫细胞及其构建方法和应用 |
CN114350608A (zh) * | 2022-01-27 | 2022-04-15 | 昭泰英基生物医药(香港)有限公司 | 一种诱导t细胞重编程为类nk细胞的组合物及其应用 |
Also Published As
Publication number | Publication date |
---|---|
AU2020359872A1 (en) | 2022-03-24 |
EP4039803A4 (en) | 2023-08-09 |
WO2021063285A1 (zh) | 2021-04-08 |
EP4039803A1 (en) | 2022-08-10 |
US20220325246A1 (en) | 2022-10-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Arcangeli et al. | Next-generation manufacturing protocols enriching TSCM CAR T cells can overcome disease-specific T cell defects in cancer patients | |
Ronchetti et al. | Glucocorticoid-induced tumour necrosis factor receptor-related protein: a key marker of functional regulatory T cells | |
CN107922925B (zh) | 用于自然杀伤细胞扩增的方法 | |
KR20200133370A (ko) | 입양 주입된 t 세포의 지속성 강화 방법 | |
WO2021063285A1 (zh) | 一种工程化人体免疫细胞、其制备方法及应用 | |
CN109790518A (zh) | 经修饰的t细胞、其制备方法及用途 | |
WO2019178518A1 (en) | Cellular signaling domain engineering in chimeric antigen receptor-modified regulatory t cells | |
Herrera et al. | Identifying SARS‐CoV‐2 ‘memory’NK cells from COVID‐19 convalescent donors for adoptive cell therapy | |
Haroun-Izquierdo et al. | Adaptive single-KIR+ NKG2C+ NK cells expanded from select superdonors show potent missing-self reactivity and efficiently control HLA-mismatched acute myeloid leukemia | |
Chimienti et al. | Engineering of immune checkpoints B7-H3 and CD155 enhances immune compatibility of MHC-I−/− iPSCs for β cell replacement | |
Plantinga et al. | Clinical grade production of wilms’ tumor-1 loaded cord blood-derived dendritic cells to prevent relapse in pediatric AML after cord blood transplantation | |
de Mey et al. | An mRNA mix redirects dendritic cells towards an antiviral program, inducing anticancer cytotoxic stem cell and central memory CD8+ T cells | |
EP4039799A1 (en) | Engineered immune killer cell, preparation method therefor and use thereof | |
KR20170047174A (ko) | 바이러스 항원 특이적인 t 세포의 유도 및 증식 방법 | |
JPWO2016093350A1 (ja) | 改変型免疫細胞、改変型免疫細胞の製造方法、およびこれらの利用 | |
CN106119193B (zh) | 一种兼有nk细胞特质的抗原特异性t细胞的制备方法 | |
US10508287B2 (en) | Method for regenerating T cells and applications thereof | |
Liu et al. | EX VIVO EXPANDED HUMAN V? 9V? 2+??-T CELLS MEDIATE INNATE ANTITUMOR ACTIVITY AGAINST HUMAN PROSTATE CANCER CELLS IN VITRO | |
Ferreira et al. | Reprogramming Cancer Cells to Antigen-presenting Cells | |
Hojjatipour et al. | Chimeric antigen receptor-natural killer cells: a promising sword against insidious tumor cells | |
Garcés Lázaro | Restoring NK cells function against cancer. | |
WO2023125860A1 (zh) | 通用型car-t细胞的制备技术及其应用 | |
CN109295106B (zh) | 一种hafft1细胞 | |
US20240052309A1 (en) | Method for producing regenerated t cell via ips cell | |
Gerstner et al. | Specific phenotype and function of CD56-expressing innate immune cell subsets in human thymus |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |